GAUSH MEDITECH LTD |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.3 HKD | -3.02% |
|
-3.40% | -48.94% |
| May. 02 | Gaush Meditech Swings to Profit in 2023 | MT |
| Apr. 23 | Gaush Meditech Ltd Announces Change in Joint Company Secretary | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 49% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- With a P/E ratio at 12.28 for the current year and 9.75 for next year, earnings multiples are highly attractive compared with competitors.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -48.94% | 378M | - | ||
| -2.96% | 9.41B | B+ | ||
| -0.02% | 1.44B | D | ||
| -6.59% | 1.38B | B+ | ||
| -13.57% | 1.11B | - | ||
| -16.87% | 873M | - | - | |
| -1.34% | 463M | - | ||
| +3.28% | 440M | - | - | |
| -21.49% | 348M | - | - | |
| -3.34% | 211M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 2407 Stock
- Ratings Gaush Meditech Ltd